NCT06420271 Effects of Cerebellar tACS-iTBS in Ataxia
| NCT ID | NCT06420271 |
| Status | Recruiting |
| Phase | — |
| Sponsor | I.R.C.C.S. Fondazione Santa Lucia |
| Condition | Ataxia |
| Study Type | INTERVENTIONAL |
| Enrollment | 30 participants |
| Start Date | 2025-05-01 |
| Primary Completion | 2026-09-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 30 participants in total. It began in 2025-05-01 with a primary completion date of 2026-09-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Ataxia refers to a group of neurological disorders characterized by impaired coordination and balance due to dysfunction in the cerebellum or its connections. Traditional therapeutic approaches for ataxia have shown limited efficacy, prompting researchers to explore alternative interventions. Non-invasive brain stimulation (NIBS) techniques, such as transcranial magnetic stimulation (TMS), transcranial direct current stimulation (tDCS), transcranial alternating current stimulation (tACS), and intermittent theta burst stimulation (iTBS), have emerged as potential therapeutic options. The aim of this study is to investigate the combined effect of tACS-iTBS on balance functions in ataxia disorders.
Eligibility Criteria
Inclusion Criteria: 1. Confirmed diagnosis of ataxia based on clinical assessment and/or neuroimaging findings. 2. Stable medication regimen for at least four weeks prior to the study. 3. Sufficient cognitive ability to understand and comply with study instructions. Exclusion Criteria: 1. History of seizures. 2. Severe general impairment or concomitant diseases. 3. Intracranial metal implants. 4. Cardiac pacemaker. 5. Pregnancy status.
Contact & Investigator
Danny Spampinato, PhD
STUDY CHAIR
University of Roma La Sapienza
Frequently Asked Questions
Who can join the NCT06420271 clinical trial?
This trial is open to participants of all sexes, aged 8 Years or older, up to 80 Years, studying Ataxia. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06420271 currently recruiting?
Yes, NCT06420271 is actively recruiting participants. Contact the research team at g.koch@hsantalucia.it for enrollment information.
Where is the NCT06420271 trial being conducted?
This trial is being conducted at Rome, Italy.
Who is sponsoring the NCT06420271 clinical trial?
NCT06420271 is sponsored by I.R.C.C.S. Fondazione Santa Lucia. The principal investigator is Danny Spampinato, PhD at University of Roma La Sapienza. The trial plans to enroll 30 participants.